COVID-19 coronavirus disease is an often-severe illness caused by the SARS-CoV-2 virus. The pandemic has demanded a great organization and redistribution of infrastructure and medical resources for the care of patients with cancer. The Gynecology service of the Oncology Hospital of the City of Buenos Aires is a monovalent center dependent on the City of Buenos Aires. It is part of the network of 33 public hospitals in the City of Buenos Aires and receives referrals from other hospitals in the network and from hospitals in the Province of Buenos Aires. As of March 20, 2020, when decree 260/20 came into force, which established social, preventive and compulsory isolation, a new modality was started for the care and benefits of our hospital. In our Service of the Hospital de Oncología de la Ciudad de Buenos Aires we have developed recommendations for the management of gynecological tumors during the COVID-19. The guide we developed is based on up-to-date data and available resources and provides suggestions and tools for decision-making in order to reduce the morbidity and mortality of patients with gynecological cancer during the Coronavirus pandemic (COVID-19).
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA Trial.
Circ Cardiovasc Interv
June 2024
Department of Medicine, Stanford University, CA (D.J.M.).
Background: ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) did not find an overall reduction in cardiovascular events with an initial invasive versus conservative management strategy in chronic coronary disease; however, there were conservative strategy participants who underwent invasive coronary angiography early postrandomization (within 6 months). Identifying factors associated with angiography in conservative strategy participants will inform clinical decision-making in patients with chronic coronary disease.
Methods: Factors independently associated with angiography performed within 6 months of randomization were identified using Fine and Gray proportional subdistribution hazard models, including demographics, region of randomization, medical history, risk factor control, symptoms, ischemia severity, coronary anatomy based on protocol-mandated coronary computed tomography angiography, and medication use.
Early mobilisation in critically ill COVID-19 patients: a subanalysis of the ESICM-initiated UNITE-COVID observational study.
Ann Intensive Care
November 2023
Charité - Universitätsmedizin Berlin, corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Anesthesiology and Intensive Care Medicine (CCM/CVK), Berlin, Germany.
Background: Early mobilisation (EM) is an intervention that may improve the outcome of critically ill patients. There is limited data on EM in COVID-19 patients and its use during the first pandemic wave.
Methods: This is a pre-planned subanalysis of the ESICM UNITE-COVID, an international multicenter observational study involving critically ill COVID-19 patients in the ICU between February 15th and May 15th, 2020.
Surgical site infection in bariatric surgery: results of a care bundle.
Rev Col Bras Cir
September 2019
Universidade Federal de Pernambuco, Centro de Ciências da Saúde, Departamento de Cirurgia, Recife, PE, Brasil.
Objective: to present a descriptive analysis of the results of a care bundle applied to obese patients submitted to bariatric surgery, regarding infection control.
Methods: a care bundle was designed to control surgical site infection (SSI) rates in patients undergoing bariatric surgery. The bundle included smoking cessation, bathing with 4% chlorhexidine two hours before surgery, cefazolin (2g bolus) in anesthetic induction associated with a continuous infusion of the same drug at a dose of 1g over a two-hour period, appropriate trichotomy, glycemic control, supplemental oxygen, normothermia, intraspinal morphine for the relief of pain, and sterile dressing removal 48 hours after surgery.
Update on biomarkers in neuromyelitis optica.
Neurol Neuroimmunol Neuroinflamm
August 2015
Stanford University (E.M., M.H.H.), Stanford, CA; Johns Hopkins University (M.L.), Baltimore, MD; University of Oxford (P.J.W.), UK; Tohoku University (D.K.S.), Sendai, Japan; University of São Paulo (D.K.S.), Brazil; University of Colorado (J.L.B.), Denver; Mt. Sinai University (G.R.J.), New York, NY; Thomas Jefferson University (D.C.H.), Philadelphia, PA; IDIBAPS (A.S.), Barcelona, Spain; Montreal Neurological Institute and Hospital (A.B.-O.), McGill University, Montreal, Quebec, Canada; Research Institute and Hospital of National Cancer Center (H.J.K.), Goyang, Korea; KS Hegde Medical Academy (L.P.), Nitte University, Mangalore, India; Oxford University Hospital (M.I.L.), Oxford, UK; University of Southern Denmark (N.A.), Odense; Vejle Hospital (N.A.), Denmark; University Hospital (N.K.), Marrakech, Morocco; MS Center (R.H.), Erasmus MC University Medical Center, Rotterdam, the Netherlands; Service de Neurologie A (R.M.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France; Molecular Neuroimmunology (S.J.), Department of Neurology, University Hospital Heidelberg, Germany; Tandem Labs (J.M.), San Diego, CA; University of Michigan Medical School (T.J.S.), Ann Arbor, MI; and David Geffen School of Medicine (M.R.Y.), University of California, Los Angeles.
Neuromyelitis optica (NMO) (and NMO spectrum disorder) is an autoimmune inflammatory disease of the CNS primarily affecting spinal cord and optic nerves. Reliable and sensitive biomarkers for onset, relapse, and progression in NMO are urgently needed because of the heterogeneous clinical presentation, severity of neurologic disability following relapses, and variability of therapeutic response. Detecting aquaporin-4 (AQP4) antibodies (AQP4-IgG or NMO-IgG) in serum supports the diagnosis of seropositive NMO.
View Article and Find Full Text PDFThe IASLC/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignancies.
J Thorac Oncol
December 2013
*Department of Thoracic Surgery, Yale New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut; †Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan; ‡Biostatistics, Cancer Research And Biostatistics, Seattle, Washington; §Radiation Oncology, Queen's University, Ontario, Canada; ‖Medical Oncology, National Cancer Institute, Bethesda, Maryland; ¶Thoracic Surgery, Sloan-Kettering Cancer Center, New York, New York; #Thoracic Surgery, Samsung Medical Center, Seoul, South Korea; **Thoracic Surgery, University of Tokushima, Tokushima, Japan; ††Thoracic Surgery, University of Pisa, Pisa, Italy; ‡‡Pathology, Regina Elena National Cancer Institute, Rome, Italy; §§Radiology, MD Anderson Cancer Center, Houston, Texas; ‖‖Pathology, Royal Brompton Hospital, London, United Kingdom; ¶¶Thoracic Surgery, Osaka University, Osaka, Japan; ##Thoracic Surgery, University of Torino, Torino, Italy; ***Thoracic Surgery, Antwerp University Hospital, Antwerp, Belgium; ††† Members of the Staging and Prognostic Factors Committee are listed in the Appendix 1; ‡‡‡ Members of the Advisory Boards are listed in the Appendices 2, 3, and 4; and §§§ Members of the Participating Institutions of the Thymic Domain are listed in the Appendix 5.
The lack of an official-stage classification system for thymic malignancies is an issue that hampers progress in this rare disease. A collaborative effort by the International Association for the Study of Lung Cancer and the International Thymic Malignancies Interest Group is underway to develop proposals for such a system. A database of more than 10,000 cases worldwide has been assembled to provide a solid basis for analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!